IL6 and colitis: Previous studies demonstrated that Uro-A reduced colon inflammation and improved intestinal barrier integrity in DSS-induced mouse models of colitis by reducing the cytokines interleukin 1 beta (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNFα).